EMA Withdrawn: Olysio (simeprevir) — Janssen-Cilag International NV

View source ↗

Summary

Olysio (simeprevir) has been withdrawn from the market by Janssen-Cilag International NV in relation to chronic hepatitis C.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Olysio (Simeprevir)

Snippet

Status: Withdrawn. Therapeutic area: Hepatitis C, Chronic. MAH: Janssen-Cilag International NV. Decision date: 08/02/2018